The annual impact of seasonal influenza in the US: measuring disease burden and costs
- PMID: 17544181
- DOI: 10.1016/j.vaccine.2007.03.046
The annual impact of seasonal influenza in the US: measuring disease burden and costs
Abstract
Background: Despite preventive efforts, influenza epidemics are responsible for substantial morbidity and mortality every year in the United States (US). Vaccination strategies to reduce disease burden have been implemented. However, no previous studies have systematically estimated the annual economic burden of influenza epidemics, an estimate necessary to guide policy makers effectively.
Objective: We estimate age- and risk-specific disease burden, and medical and indirect costs attributable to annual influenza epidemics in the United States.
Methods: Using a probabilistic model and publicly available epidemiological data we estimated the number of influenza-attributable cases leading to outpatient visits, hospitalization, and mortality, as well as time lost from work absenteeism or premature death. With data from health insurance claims and projections of either earnings or statistical life values, we then estimated healthcare resource utilization associated with influenza cases as were their medical and productivity (indirect) costs in $2003.
Results: Based on 2003 US population, we estimated that annual influenza epidemics resulted in an average of 610,660 life-years lost (undiscounted), 3.1 million hospitalized days, and 31.4 million outpatient visits. Direct medical costs averaged $10.4 billion (95% confidence interval [C.I.], $4.1, $22.2) annually. Projected lost earnings due to illness and loss of life amounted to $16.3 billion (C.I., $8.7, $31.0) annually. The total economic burden of annual influenza epidemics using projected statistical life values amounted to $87.1 billion (C.I., $47.2, $149.5).
Conclusions: These results highlight the enormous annual burden of influenza in the US. While hospitalization costs are important contributors, lost productivity from missed work days and lost lives comprise the bulk of the economic burden of influenza.
Similar articles
-
Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.Vaccine. 2006 Nov 17;24(47-48):6812-22. doi: 10.1016/j.vaccine.2006.07.042. Epub 2006 Aug 4. Vaccine. 2006. PMID: 17034909
-
The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population.PLoS One. 2017 Jan 3;12(1):e0169344. doi: 10.1371/journal.pone.0169344. eCollection 2017. PLoS One. 2017. PMID: 28046080 Free PMC article.
-
Seasonal influenza: an overview.J Sch Nurs. 2009 Feb;25 Suppl 1:4S-12S. doi: 10.1177/1059840508330066. J Sch Nurs. 2009. PMID: 19197008 Review.
-
The burden of illness associated with renal cell carcinoma in the United States.Urol Oncol. 2007 Sep-Oct;25(5):368-75. doi: 10.1016/j.urolonc.2007.02.014. Urol Oncol. 2007. PMID: 17826652
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
Cited by
-
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.NPJ Vaccines. 2024 Nov 17;9(1):222. doi: 10.1038/s41541-024-01014-8. NPJ Vaccines. 2024. PMID: 39551795 Free PMC article.
-
Impact of COVID-19 pandemic on influenza vaccination rate among health care workers.Hum Vaccin Immunother. 2024 Dec 31;20(1):2426284. doi: 10.1080/21645515.2024.2426284. Epub 2024 Nov 10. Hum Vaccin Immunother. 2024. PMID: 39523588 Free PMC article.
-
Respiratory virus infections in symptomatic and asymptomatic children upon hospital admission: new insights.Antimicrob Steward Healthc Epidemiol. 2024 Oct 7;4(1):e162. doi: 10.1017/ash.2024.407. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 39411664 Free PMC article.
-
Incorporating connectivity among Internet search data for enhanced influenza-like illness tracking.PLoS One. 2024 Aug 26;19(8):e0305579. doi: 10.1371/journal.pone.0305579. eCollection 2024. PLoS One. 2024. PMID: 39186560 Free PMC article.
-
Germacrone: A Multi-targeting Sesquiterpene with Promising Anti-cancer and Chronic Disease Applications.Anticancer Agents Med Chem. 2024;24(19):1396-1406. doi: 10.2174/0118715206312324240805075050. Anticancer Agents Med Chem. 2024. PMID: 39113300
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
